Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Kidney Involvement
75%
Avacopan
66%
Real-world Experience
66%
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
66%
Large Vessel Vasculitis
66%
Scleroderma Renal Crisis
66%
Antineutrophil Cytoplasmic Antibody
66%
Antibody-mediated
66%
Pauci-immune
66%
Angiotensin-converting Enzyme Inhibitor (ACEi)
44%
Blood Pressure
44%
Systemic Sclerosis
44%
Plasma Exchange
30%
Tendon Friction Rubs
22%
Thrombocytopenia
22%
Corticosteroid Use
22%
Oliguria
22%
Medical Therapy
22%
Severe Hypertension
22%
Calcium Channel Blockers
22%
Classification Criteria
22%
Early Treatment
22%
Mortality Rate
22%
Adjunctive Therapy
22%
Early Recognition
22%
Diastolic Blood Pressure
22%
Baseline Blood Pressure
22%
Rapidly Progressive
22%
Abrupt Onset
22%
Acute Kidney Injury
22%
Diffuse Cutaneous Systemic Sclerosis
22%
Renal Replacement Therapy
22%
Eculizumab
22%
Systolic Blood Pressure
22%
Life-threatening Complications
22%
Endothelin Receptor Antagonist
22%
Reduced Mortality
22%
Flash Pulmonary Edema
22%
Angiotensin Receptor Blockers
22%
Skin Thickening
22%
Renal Transplant
22%
Improved Outcomes
22%
Renal Biopsy
22%
Joint Contracture
22%
Raynaud's Phenomenon
22%
Large Joint
22%
Novel Classification
22%
Hemodialysis
22%
Kidney Disease Progression
22%
Microangiopathic Hemolytic Anemia
22%
Medicine and Dentistry
Cyclophosphamide
75%
Avacopan
66%
Autoantibodies
66%
Vasculitis
66%
Small Vessel Vasculitis
66%
Pauci-Immune
66%
Neutrophil Cytoplasmic Antibody
66%
Scleroderma
66%
Systemic Scleroderma
66%
Cohort Analysis
66%
Membranous Glomerulonephritis
66%
Blood Pressure
44%
ACE Inhibitor
44%
Renal Replacement Therapy
30%
Plasma Exchange
30%
Oliguria
22%
Eculizumab
22%
Mortality Rate
22%
Angiotensin Receptor Antagonist
22%
Thrombocytopenia
22%
Flash Pulmonary Edema
22%
Systolic Blood Pressure
22%
Calcium Channel Blocking Agent
22%
Renal Biopsy
22%
Receptor Antagonist
22%
DNA Directed RNA Polymerase III
22%
Acute Kidney Injury
22%
Joint Contracture
22%
Renal Failure
22%
Alpha Adrenergic Receptor Blocking Agent
22%
Thrombotic Thrombocytopenic Purpura
22%
Adjuvant Therapy
22%
Diastolic Blood Pressure
22%
Endothelin 1
22%
Kidney Graft
22%
Corticosteroid
22%
Hypertension
22%
Oral
18%
Glucocorticoid
18%
Glomerular Filtration Rate
16%
ANCA Associated Vasculitis
16%
Low Drug Dose
14%
Treatment Duration
12%
Adverse Event
12%
Combination Therapy
8%
Adverse Event
8%
Logistic Regression Analysis
8%
Rituximab
8%
Prednisone
8%
Transaminase
8%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Cyclophosphamide
75%
Vasculitis
66%
Membranous Glomerulonephritis
66%
Autoantibodies
66%
Cohort Study
66%
Avacopan
66%
Adverse Event
20%
Glucocorticoid
18%
ANCA Associated Vasculitis
16%
Nephrotic Syndrome
12%
Combination Therapy
8%
Rituximab
8%
Aminotransferase
8%
Replacement Therapy
8%
Prednisone
8%
Clinical Trial
6%
Low Drug Dose
6%